Skip to main content
SLDB
NASDAQ Life Sciences

Solid Biosciences Q3 Loss Widens to $53.9M; $348.9M Cash Funds Runway Into 1H 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$6.52
Mkt Cap
$699.109M
52W Low
$3.79
52W High
$11.45
52W Position info
72% above low
Off High info
43% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

SLDB sits 72% above its 52-week low of $3.79.

Summary

Solid Biosciences posted a $53.9M third-quarter net loss on higher R&D and G&A spending, while $348.9M in cash and investments funds operations into the first half of 2028. A Type C FDA meeting on SGT-003's potential accelerated approval path is set for late Q4 2026.


Key Events · Earnings and Guidance · SLDB

  • Q3 Net Loss Widens to $53.9M

    Third-quarter net loss was $53.9M versus $45.8M a year earlier, and the nine-month net loss reached $165.5M versus $124.5M.

  • Cash Runway Into 1H 2028

    Cash, cash equivalents and available-for-sale securities totaled $348.9M at September 30, 2026, excluding $1.3M restricted cash, which funds operations into the first half of 2028.

  • R&D and G&A Spending Jump

    R&D rose 12.2% to $43.6M in Q3, driven by SGT-003 manufacturing and clinical costs up $2.0M and SGT-212 up $2.6M; G&A rose 52.9% to $14.1M on personnel and commercial-readiness costs.

  • FDA Type C Meeting Set for Late Q4 2026

    The company scheduled a Type C meeting with the FDA late in Q4 2026 to discuss the preliminary INSPIRE DUCHENNE SGT-003 data package and a potential accelerated approval pathway; 53 participants had been dosed as of November 3, 2026.


Analysis · SLDB · Life Sciences

The balance sheet is the real story here: $348.9M in cash and securities funds operations into the first half of 2028, so there is no near-term financing pressure, even as the loss widened on scaled-up spending for SGT-003 manufacturing and clinical work. The key swing factor is the Type C meeting with the FDA scheduled for late in the fourth quarter of 2026 to discuss the INSPIRE DUCHENNE data package and a potential accelerated approval pathway; the outcome will shape the SGT-003 regulatory path. Note that the company has been funding itself partly through the ATM, selling 10.5M shares for $76.5M net in the first nine months.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SLDB was trading at $6.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $699.1M. The 52-week trading range was $3.79 to $11.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SLDB - Latest Insights

SLDB
Nov 04, 2026, 4:07 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $6.52
Real-time Price: $6.44 info
Change: -$0.080 (-1%) info
Market Cap: $718.772M info
SLDB
Aug 14, 2026, 5:22 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $9.38
Real-time Price: $6.44 info
Change: -$2.94 (-31%) info
Market Cap: $718.772M info
SLDB
Aug 06, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.25
Real-time Price: $6.44 info
Change: -$1.81 (-22%) info
Market Cap: $718.772M info
SLDB
Aug 06, 2026, 4:23 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $8.65
Real-time Price: $6.44 info
Change: -$2.21 (-26%) info
Market Cap: $718.772M info
SLDB
Jun 24, 2026, 6:49 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $9.29
Real-time Price: $6.44 info
Change: -$2.85 (-31%) info
Market Cap: $718.772M info